A biotech firm slashed diagnostic delays by 30% after embracing the Rare Disease Data Center. See how centralizing genomics and registry data translates into faster trials and stronger ROI.
A biotech firm slashed diagnostic delays by 30% after embracing the Rare Disease Data Center. See how centralizing genomics and registry data translates into fa

A biotech firm slashed diagnostic delays by 30% after embracing the Rare Disease Data Center. See how centralizing genomics and registry data translates into faster trials and stronger ROI.
Read the original article and join the discussion on Dev.to
Read on Dev.to


When a child's rare disease goes undiagnosed, hidden AI logic can delay care. DeepRare adds a transp...


A child waited months for a rare disease answer. West AI used the FDA database to deliver a diagnosi...


When the rare disease data hub merged millions of records in 2023, enrollment timelines collapsed an...


A 32% boost in variant prioritization shows the Rare Disease Data Center is thriving, not failing. D...


A 30% cut in time from biopsy to therapy means children get life‑saving treatment faster. Discover t...


80% of rare disease patients wait years for a diagnosis. A new data center promises to shrink that t...